

NCIRS is conducting GRADE in support of ATAGI and making pilot results available on the NCIRS website. Please read this material as a supplement to the [Australian Immunisation Handbook Meningococcal Chapter](#)

Summary of Findings: Bexsero booster vaccine compared to no booster for individuals at increased risk of invasive meningococcal disease

Patient or population: Individuals at increased risk of IMD

Intervention: Bexsero booster dose

Comparison: No booster

Outcome № of participants (studies)	Impact	Certainty	Interpretation
CRITICAL OUTCOMES			
<p>Proportion of infant (<2 years) participants with hSBA $\geq 1:4$ (hSBA$\geq 1:4$) follow-up: 1 months № of participants: 417^A (5 observational studies^{3-5,7,9})</p>		<p>⊕ ⊙ ⊙ ⊙ Very low^{a,b,c}</p>	<p>The evidence is very uncertain about the effect of Bexsero on hSBA$\geq 1:4$. Bexsero booster may increase the proportion of infants (<2 years) with hSBA$\geq 1:4$ but the evidence is very uncertain</p>


Outcome
 № of participants
 (studies)

Impact

Certainty

Interpretation

Proportion of participants aged >2 years with hSBA \geq 1:4
 (hSBA \geq 1:4)
 follow-up: 1 months
 № of participants: 405[^] (3 observational studies⁶⁻⁸)




Very low^{a,b,c}

The evidence is very uncertain about the effect of Bexsero on hSBA \geq 1:4. Bexsero booster vaccine may increase the proportion of individuals >2 years of age with hSBA \geq 1:4 but the evidence is very uncertain

Outcome № of participants (studies)	Impact	Certainty	Interpretation
---	--------	-----------	----------------


Persistence: Proportion of infant (<2 years) participants with hSBA $\geq 1:4$
 follow-up: 24 months
 № of participants: 33 (2 observational studies^{4,5})



⊕○○○
 Very low^{a,b,d}

The evidence is very uncertain about the effect of Bexsero booster on hSBA $\geq 1:4$ persistence.
 Bexsero may increase the proportion of infants (<2 years) with hSBA $\geq 1:4$ at 24 months post booster vaccine but the evidence is very uncertain

Persistence: Proportion of participants aged >2 years with hSBA $\geq 1:4$
 follow-up: 12 months
 № of participants: 11 (1 observational study⁸)



⊕○○○
 Very low^{a,b,d}


The evidence is very uncertain about the effect of Bexsero booster on hSBA $\geq 1:4$ persistence.
 Bexsero may increase the proportion of individuals >2 years of age with hSBA $\geq 1:4$ at 12 months post booster vaccine but the evidence is very uncertain.

Outcome № of participants (studies)	Impact	Certainty	Interpretation																																							
<p>Geometric mean ratio (GMR) in infants (<2 years) № of participants: 155[^] (3 observational studies³⁻⁵)</p>	<table border="1"> <caption>Approximate GMR (log) values from the chart</caption> <thead> <tr> <th>Study</th> <th>Vaccine Formulation</th> <th>M10713 (NHBA)</th> <th>Nz98/254 (OMV/PorA)</th> <th>5/99 (NadA)</th> <th>H44/76 (fHbp)</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Sadarangani 2017</td> <td>4CMenB24-26m</td> <td>~8</td> <td>~25</td> <td>~50</td> <td>~120</td> </tr> <tr> <td>4CMenB18-20m</td> <td>~8</td> <td>~15</td> <td>~40</td> <td>~60</td> </tr> <tr> <td>4CMenB12-14m</td> <td>~6</td> <td>~20</td> <td>~45</td> <td>~100</td> </tr> <tr> <td rowspan="1">Snape 2013b</td> <td>4CMenB68-12m</td> <td>~4</td> <td>~15</td> <td>~30</td> <td>~40</td> </tr> <tr> <td rowspan="2">Snape 2013a</td> <td>4CMenB-12m</td> <td>~10</td> <td>~150</td> <td>~400</td> <td>~20</td> </tr> <tr> <td>4CMenB246-12m</td> <td>~10</td> <td>~15</td> <td>~40</td> <td>~15</td> </tr> </tbody> </table>	Study	Vaccine Formulation	M10713 (NHBA)	Nz98/254 (OMV/PorA)	5/99 (NadA)	H44/76 (fHbp)	Sadarangani 2017	4CMenB24-26m	~8	~25	~50	~120	4CMenB18-20m	~8	~15	~40	~60	4CMenB12-14m	~6	~20	~45	~100	Snape 2013b	4CMenB68-12m	~4	~15	~30	~40	Snape 2013a	4CMenB-12m	~10	~150	~400	~20	4CMenB246-12m	~10	~15	~40	~15	<p>⊕○○○ Very low^{a,b,c}</p>	<p>The evidence is very uncertain about the effect of Bexsero on GMR. Bexsero booster vaccine may increase in post-booster vs pre-booster titres as measured by GMR in infants (<2 years) but the evidence is very uncertain.</p>
Study	Vaccine Formulation	M10713 (NHBA)	Nz98/254 (OMV/PorA)	5/99 (NadA)	H44/76 (fHbp)																																					
Sadarangani 2017	4CMenB24-26m	~8	~25	~50	~120																																					
	4CMenB18-20m	~8	~15	~40	~60																																					
	4CMenB12-14m	~6	~20	~45	~100																																					
Snape 2013b	4CMenB68-12m	~4	~15	~30	~40																																					
Snape 2013a	4CMenB-12m	~10	~150	~400	~20																																					
	4CMenB246-12m	~10	~15	~40	~15																																					

Outcome № of participants (studies)	Impact	Certainty	Interpretation
<p>Geometric mean ratio (GMR) in participants aged >2 years № of participants: 137^ (2 observational studies^{6,8})</p>	<p>Legend: ■ M10713 (NHBA) ■ Nz98/254 (OMV/PorA) ■ 5/99 (NadA) ■ H44/76 (fHbp)</p>	<p>⊕○○○ Very low^{a,b,c}</p>	<p>The evidence is very uncertain about the effect of Bexsero on GMR. Bexsero booster vaccine may increase in post-booster vs pre-booster titres as measured by GMR in individuals >2 years of age but the evidence is very uncertain.</p>
IMPORTANT OUTCOMES			

Outcome № of participants (studies)	Impact	Certainty	Interpretation
---	--------	-----------	----------------

Local adverse events (Local AEs) in infants (<2 years)
follow-up: 7 days
№ of participants: 398 (4 observational studies^{3,5,7,9})



⊕○●○
Very low^{a,b,e}


The evidence is very uncertain about the effect of Bexsero on local AEs.
Bexsero booster may increase local AEs in infants (<2 years) but the evidence is very uncertain

Outcome № of participants (studies)	Impact	Certainty	Interpretation										
<p>Local adverse events (Local AEs) in participants aged >2 years follow-up: 7 days № of participants: 405 (3 observational studies⁶⁻⁸)</p>	<p style="text-align: center;">Any local AE</p> <table border="1"> <thead> <tr> <th>Study</th> <th>Any local AE (%)</th> </tr> </thead> <tbody> <tr> <td>Szenborn 2018 (4CMenB/ABCWY10-25yoa)</td> <td>100%</td> </tr> <tr> <td>Martinon_Torres 2018 (4CMenB15-24yoa)</td> <td>~95%</td> </tr> <tr> <td>Martinon_Torres 2018 (4CMenB8-12yoa)</td> <td>~92%</td> </tr> <tr> <td>Martinon_Torres 2018 (4CMenB4-7yoa)</td> <td>~95%</td> </tr> </tbody> </table>	Study	Any local AE (%)	Szenborn 2018 (4CMenB/ABCWY10-25yoa)	100%	Martinon_Torres 2018 (4CMenB15-24yoa)	~95%	Martinon_Torres 2018 (4CMenB8-12yoa)	~92%	Martinon_Torres 2018 (4CMenB4-7yoa)	~95%	<p style="text-align: center;">⊕○○○ Very low^{a,b,e}</p>	<p>The evidence is very uncertain about the effect of Bexsero on local AEs. Bexsero booster may increase local AEs in individuals >2 years of age but the evidence is very uncertain.</p>
Study	Any local AE (%)												
Szenborn 2018 (4CMenB/ABCWY10-25yoa)	100%												
Martinon_Torres 2018 (4CMenB15-24yoa)	~95%												
Martinon_Torres 2018 (4CMenB8-12yoa)	~92%												
Martinon_Torres 2018 (4CMenB4-7yoa)	~95%												

Outcome № of participants (studies)	Impact	Certainty	Interpretation																														
<p>Systemic adverse events (Systemic AEs) in infants (<2 years) follow-up: 7 days № of participants: 398 (4 observational studies^{3,5,7,9})</p>	<p style="text-align: center;">Any systemic AE</p> <table border="1"> <thead> <tr> <th>Study</th> <th>Arm</th> <th>Percentage of Systemic AEs</th> </tr> </thead> <tbody> <tr> <td rowspan="2">Snape Martinon_Torres 2018</td> <td>4CMenB68-11m</td> <td>~72%</td> </tr> <tr> <td>4CMenB3.5-5-11m</td> <td>~68%</td> </tr> <tr> <td rowspan="4">Sadarrangani 2017</td> <td>4CMenB68-12m</td> <td>~78%</td> </tr> <tr> <td>4CMenB24-26m</td> <td>~75%</td> </tr> <tr> <td>4CMenB18-20m</td> <td>~60%</td> </tr> <tr> <td>4CMenB12-14m</td> <td>~78%</td> </tr> <tr> <td rowspan="6">Iro 2017</td> <td>4CMenB246Int24m</td> <td>~78%</td> </tr> <tr> <td>4CMenB246Int18m</td> <td>~72%</td> </tr> <tr> <td>4CMenB246Int12m</td> <td>~95%</td> </tr> <tr> <td>4CMenB246Con24m</td> <td>~82%</td> </tr> <tr> <td>4CMenB246Con18m</td> <td>~75%</td> </tr> <tr> <td>4CMenB246Con12m</td> <td>~90%</td> </tr> </tbody> </table>	Study	Arm	Percentage of Systemic AEs	Snape Martinon_Torres 2018	4CMenB68-11m	~72%	4CMenB3.5-5-11m	~68%	Sadarrangani 2017	4CMenB68-12m	~78%	4CMenB24-26m	~75%	4CMenB18-20m	~60%	4CMenB12-14m	~78%	Iro 2017	4CMenB246Int24m	~78%	4CMenB246Int18m	~72%	4CMenB246Int12m	~95%	4CMenB246Con24m	~82%	4CMenB246Con18m	~75%	4CMenB246Con12m	~90%	<p style="text-align: center;">⊕○○○ Very low^{a,b,e}</p>	<p>The evidence is very uncertain about the effect of Bexsero on systemic AEs. Bexsero booster may increase systemic AEs in infants (<2 years) but the evidence is very uncertain.</p>
Study	Arm	Percentage of Systemic AEs																															
Snape Martinon_Torres 2018	4CMenB68-11m	~72%																															
	4CMenB3.5-5-11m	~68%																															
Sadarrangani 2017	4CMenB68-12m	~78%																															
	4CMenB24-26m	~75%																															
	4CMenB18-20m	~60%																															
	4CMenB12-14m	~78%																															
Iro 2017	4CMenB246Int24m	~78%																															
	4CMenB246Int18m	~72%																															
	4CMenB246Int12m	~95%																															
	4CMenB246Con24m	~82%																															
	4CMenB246Con18m	~75%																															
	4CMenB246Con12m	~90%																															

Outcome № of participants (studies)	Impact	Certainty	Interpretation															
<p>Systemic adverse events (Systemic AEs) in participants aged >2 years follow-up: 7 days № of participants: 405 (3 observational studies⁶⁻⁸)</p>	<p style="text-align: center;">Any systemic AE</p> <table border="1"> <thead> <tr> <th>Study</th> <th>Population</th> <th>Any systemic AE (%)</th> </tr> </thead> <tbody> <tr> <td>Szenborn 2018</td> <td>4CMenB/ABCWY10-25yoa</td> <td>~55%</td> </tr> <tr> <td>Nolan 2019</td> <td>4CMenB15-24yoa</td> <td>~75%</td> </tr> <tr> <td>Martinon_Torres 2018</td> <td>4CMenB8-12yoa</td> <td>~62%</td> </tr> <tr> <td>Martinon_Torres 2018</td> <td>4CMenB4-7yoa</td> <td>~55%</td> </tr> </tbody> </table>	Study	Population	Any systemic AE (%)	Szenborn 2018	4CMenB/ABCWY10-25yoa	~55%	Nolan 2019	4CMenB15-24yoa	~75%	Martinon_Torres 2018	4CMenB8-12yoa	~62%	Martinon_Torres 2018	4CMenB4-7yoa	~55%	<p style="text-align: center;">⊕○○○ Very low^{a,b,e}</p>	<p>The evidence is very uncertain about the effect of Bexsero on systemic AEs. Bexsero booster may increase systemic AEs in individuals >2 years of age but the evidence is very uncertain.</p>
Study	Population	Any systemic AE (%)																
Szenborn 2018	4CMenB/ABCWY10-25yoa	~55%																
Nolan 2019	4CMenB15-24yoa	~75%																
Martinon_Torres 2018	4CMenB8-12yoa	~62%																
Martinon_Torres 2018	4CMenB4-7yoa	~55%																

Outcome № of participants (studies)	Impact	Certainty	Interpretation																								
<p>Unsolicited adverse events (Unsolicited AEs) in infants (<2 years) follow-up: 7 days № of participants: 384 (3 observational studies^{3,7,9})</p>	<p style="text-align: center;">Any unsolicited AE</p> <table border="1"> <caption>Data for Any unsolicited AE chart</caption> <thead> <tr> <th>Study</th> <th>Percentage of Any unsolicited AE</th> </tr> </thead> <tbody> <tr> <td>Martinon_Torres 2018 - 4CMenB68-11m</td> <td>~22%</td> </tr> <tr> <td>Martinon_Torres 2018 - 4CMenB3.5-5-11m</td> <td>~28%</td> </tr> <tr> <td>Sadamgani 2017 - 4CMenB24-26m</td> <td>~33%</td> </tr> <tr> <td>Sadamgani 2017 - 4CMenB18-20m</td> <td>~18%</td> </tr> <tr> <td>Sadamgani 2017 - 4CMenB12-14m</td> <td>~25%</td> </tr> <tr> <td>Iro 2017 - 4CMenB246Int24m</td> <td>~18%</td> </tr> <tr> <td>Iro 2017 - 4CMenB246Int18m</td> <td>~25%</td> </tr> <tr> <td>Iro 2017 - 4CMenB246Int12m</td> <td>~38%</td> </tr> <tr> <td>Iro 2017 - 4CMenB246Con24m</td> <td>~23%</td> </tr> <tr> <td>Iro 2017 - 4CMenB246Con18m</td> <td>~20%</td> </tr> <tr> <td>Iro 2017 - 4CMenB246Con12m</td> <td>~25%</td> </tr> </tbody> </table>	Study	Percentage of Any unsolicited AE	Martinon_Torres 2018 - 4CMenB68-11m	~22%	Martinon_Torres 2018 - 4CMenB3.5-5-11m	~28%	Sadamgani 2017 - 4CMenB24-26m	~33%	Sadamgani 2017 - 4CMenB18-20m	~18%	Sadamgani 2017 - 4CMenB12-14m	~25%	Iro 2017 - 4CMenB246Int24m	~18%	Iro 2017 - 4CMenB246Int18m	~25%	Iro 2017 - 4CMenB246Int12m	~38%	Iro 2017 - 4CMenB246Con24m	~23%	Iro 2017 - 4CMenB246Con18m	~20%	Iro 2017 - 4CMenB246Con12m	~25%	<p style="text-align: center;"> Very low^{a,b,e} </p>	<p>The evidence is very uncertain about the effect of Bexsero on unsolicited AEs. Bexsero booster may increase unsolicited AEs in infants (<2 years) but the evidence is very uncertain</p>
Study	Percentage of Any unsolicited AE																										
Martinon_Torres 2018 - 4CMenB68-11m	~22%																										
Martinon_Torres 2018 - 4CMenB3.5-5-11m	~28%																										
Sadamgani 2017 - 4CMenB24-26m	~33%																										
Sadamgani 2017 - 4CMenB18-20m	~18%																										
Sadamgani 2017 - 4CMenB12-14m	~25%																										
Iro 2017 - 4CMenB246Int24m	~18%																										
Iro 2017 - 4CMenB246Int18m	~25%																										
Iro 2017 - 4CMenB246Int12m	~38%																										
Iro 2017 - 4CMenB246Con24m	~23%																										
Iro 2017 - 4CMenB246Con18m	~20%																										
Iro 2017 - 4CMenB246Con12m	~25%																										

Outcome № of participants (studies)	Impact	Certainty	Interpretation																
<p>Unsolicited adverse events (Unsolicited AEs) in participants aged >2 years follow-up: 7 days № of participants: 405 (3 observational studies⁶⁻⁸)</p>	<p style="text-align: center;">Any unsolicited AE</p>  <table border="1" data-bbox="676 414 1646 798"> <thead> <tr> <th>Study</th> <th>Age Group</th> <th>Any unsolicited AE (%)</th> </tr> </thead> <tbody> <tr> <td rowspan="2">Szenborn 2018</td> <td>ACWY/ABCWY10-25yoa</td> <td>~28%</td> </tr> <tr> <td>4CMenB/ABCWY10-25yoa</td> <td>~27%</td> </tr> <tr> <td>Nolan 2019</td> <td>4CMenB15-24yoa</td> <td>~32%</td> </tr> <tr> <td rowspan="2">Martinon_Torres 2018</td> <td>4CMenB8-12yoa</td> <td>~15%</td> </tr> <tr> <td>4CMenB4-7yoa</td> <td>~28%</td> </tr> </tbody> </table>	Study	Age Group	Any unsolicited AE (%)	Szenborn 2018	ACWY/ABCWY10-25yoa	~28%	4CMenB/ABCWY10-25yoa	~27%	Nolan 2019	4CMenB15-24yoa	~32%	Martinon_Torres 2018	4CMenB8-12yoa	~15%	4CMenB4-7yoa	~28%	<p style="text-align: center;">⊕○○○ Very low^{a,b,e}</p>	<p>The evidence is very uncertain about the effect of Bexsero on unsolicited AEs. Bexsero booster may increase unsolicited AEs in individuals >2 years of age but the evidence is very uncertain</p>
Study	Age Group	Any unsolicited AE (%)																	
Szenborn 2018	ACWY/ABCWY10-25yoa	~28%																	
	4CMenB/ABCWY10-25yoa	~27%																	
Nolan 2019	4CMenB15-24yoa	~32%																	
Martinon_Torres 2018	4CMenB8-12yoa	~15%																	
	4CMenB4-7yoa	~28%																	

Outcome № of participants (studies)	Impact	Certainty	Interpretation																												
<p>Fever $\geq 38^{\circ}\text{C}$ (Fever) in infants (<2 years) follow-up: 7 days № of participants: 417 (5 observational studies^{3-5,7,9})</p>	<p style="text-align: center;">Fever $\geq 38^{\circ}\text{C}$</p> <table border="1"> <caption>Forest Plot Data: Fever $\geq 38^{\circ}\text{C}$</caption> <thead> <tr> <th>Study</th> <th>Impact (%)</th> </tr> </thead> <tbody> <tr><td>4CMenB68-11m</td><td>~13%</td></tr> <tr><td>4CMenB3.5-5-11m</td><td>~20%</td></tr> <tr><td>4CMenB68-12m</td><td>~8%</td></tr> <tr><td>4CMenB246-12m</td><td>~5%</td></tr> <tr><td>4CMenB24-26m</td><td>~42%</td></tr> <tr><td>4CMenB18-20m</td><td>~40%</td></tr> <tr><td>4CMenB12-14m</td><td>~15%</td></tr> <tr><td>4CMenB246Int24m</td><td>~6%</td></tr> <tr><td>4CMenB246Int18m</td><td>~4%</td></tr> <tr><td>4CMenB246Int12m</td><td>~10%</td></tr> <tr><td>4CMenB246Con24m</td><td>~18%</td></tr> <tr><td>4CMenB246Con18m</td><td>~14%</td></tr> <tr><td>4CMenB246Con12m</td><td>~20%</td></tr> </tbody> </table>	Study	Impact (%)	4CMenB68-11m	~13%	4CMenB3.5-5-11m	~20%	4CMenB68-12m	~8%	4CMenB246-12m	~5%	4CMenB24-26m	~42%	4CMenB18-20m	~40%	4CMenB12-14m	~15%	4CMenB246Int24m	~6%	4CMenB246Int18m	~4%	4CMenB246Int12m	~10%	4CMenB246Con24m	~18%	4CMenB246Con18m	~14%	4CMenB246Con12m	~20%	<p style="text-align: center;"> Very low^{a,b,e} </p>	<p>The evidence is very uncertain about the effect of Bexsero on fever. Bexsero booster may increase fever $\geq 38^{\circ}\text{C}$ in infants (<2 years) but the evidence is very uncertain.</p>
Study	Impact (%)																														
4CMenB68-11m	~13%																														
4CMenB3.5-5-11m	~20%																														
4CMenB68-12m	~8%																														
4CMenB246-12m	~5%																														
4CMenB24-26m	~42%																														
4CMenB18-20m	~40%																														
4CMenB12-14m	~15%																														
4CMenB246Int24m	~6%																														
4CMenB246Int18m	~4%																														
4CMenB246Int12m	~10%																														
4CMenB246Con24m	~18%																														
4CMenB246Con18m	~14%																														
4CMenB246Con12m	~20%																														

Outcome № of participants (studies)	Impact	Certainty	Interpretation															
Fever $\geq 38^{\circ}\text{C}$ (Fever) in participants aged >2 years follow-up: 7 days № of participants: 405 (3 observational studies ⁶⁻⁸)	<table border="1"> <caption>Fever $\geq 38^{\circ}\text{C}$ Data</caption> <thead> <tr> <th>Study</th> <th>Population</th> <th>Percentage of Participants with Fever</th> </tr> </thead> <tbody> <tr> <td>Szenborn 2018</td> <td>4CMenB/ABCWY10-25yoa</td> <td>~10%</td> </tr> <tr> <td>Nolan 2019</td> <td>4CMenB15-24yoa</td> <td>~8%</td> </tr> <tr> <td>Martinon_Torres 2018</td> <td>4CMenB8-12yoa</td> <td>~12%</td> </tr> <tr> <td>Martinon_Torres 2018</td> <td>4CMenB4-7yoa</td> <td>~8%</td> </tr> </tbody> </table>	Study	Population	Percentage of Participants with Fever	Szenborn 2018	4CMenB/ABCWY10-25yoa	~10%	Nolan 2019	4CMenB15-24yoa	~8%	Martinon_Torres 2018	4CMenB8-12yoa	~12%	Martinon_Torres 2018	4CMenB4-7yoa	~8%	Very low ^{a,b,e}	The evidence is very uncertain about the effect of Bexsero on fever. Bexsero booster may have little to no effect on fever $\geq 38^{\circ}\text{C}$ in individuals >2 years of age but the evidence is very uncertain.
Study	Population	Percentage of Participants with Fever																
Szenborn 2018	4CMenB/ABCWY10-25yoa	~10%																
Nolan 2019	4CMenB15-24yoa	~8%																
Martinon_Torres 2018	4CMenB8-12yoa	~12%																
Martinon_Torres 2018	4CMenB4-7yoa	~8%																

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

- a. Single arm comparison, assessed as serious risk of bias using ROBINS-I
 - b. The population included in the studies are healthy participants without an increased risk of IMD
 - c. Low sample size (<400 participants). Confidence intervals overlap within some strains
 - d. Very low sample size (<50 participants)
 - e. Low number of events (<300 events)
- [^]number of participants includes those included in the analysis post booster dose and does not double count the 'pre booster' participants

GRADE Evidence Profile: Bexsero booster compared to no booster in individuals at increased risk of IMD

Certainty assessment							Impact	Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations			
Proportion of participants with hSBA \geq1:4 (follow-up: 1 months)									
5	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Proportion of participants with hSBA \geq 1:4 at 1 month post booster vaccine ranged from 70-100% in infants (<2 years)	⊕○○○ Very low	CRITICAL
3	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Proportion of participants with hSBA \geq 1:4 at 1 month post booster vaccine ranged from 82-100% in participants aged >2 years	⊕○○○ Very low	CRITICAL
Proportion of participants with hSBA \geq1:4 (persistence) (follow-up: 24 months)									
2	observational studies	serious ^a	not serious	serious ^b	very serious ^d	none	Proportion of participants with hSBA \geq 1:4 at 24 months post booster vaccine ranged from 17-100% in infants (<2 years)	⊕○○○ Very low	CRITICAL
1	observational studies	serious ^a	NA*	serious ^b	very serious ^d	none	Proportion of participants with hSBA \geq 1:4 at 12 months post booster vaccine ranged from 45-100%	⊕○○○ Very low	CRITICAL
Geometric mean ratio									
3	observational studies	serious ^a	not serious	serious ^b	serious ^c	none	The GMR in infants (<2 years) before and after booster vaccination ranged from 3.25-509	⊕○○○ Very low	CRITICAL
2	observational studies	serious ^a	not serious	serious ^b	serious ^c	none	The GMR in participants aged >2 years before and after booster vaccination ranged from 4.69-525	⊕○○○ Very low	CRITICAL
Local adverse events (follow-up: 7 days)									
4	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Local AEs ranged from 84-100% in infants (<2 years)	⊕○○○ Very low	IMPORTANT
3	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Local AEs ranged from 93-100% in participants aged >2 years	⊕○○○ Very low	IMPORTANT
Systemic adverse events (follow-up: 7 days)									
4	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Systemic AEs ranged from 60-95% infants (<2 years)	⊕○○○ Very low	IMPORTANT
3	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Systemic AEs ranged from 55-76% in participants aged >2 years	⊕○○○ Very low	IMPORTANT
Unsolicited adverse events (follow-up: 7 days)									
3	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Unsolicited AEs ranged from 18-37% infants (<2 years)	⊕○○○ Very low	IMPORTANT

Certainty assessment							Impact	Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations			
3	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Unsolicited AEs ranged from 15-32% in participants aged >2 years	⊕⊕○○ Low	IMPORTANT

Fever ≥38°C (follow-up: 7 days)

5	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Fever ≥38°C ranged from 4-42% infants (<2 years)	⊕○○○ Very low	IMPORTANT
3	observational studies	serious ^a	not serious	serious ^b	serious ^d	none	Fever ≥38°C ranged from 0-11% in participants aged >2 years	⊕○○○ Very low	IMPORTANT

Explanations

- a. Single arm comparison, assessed as serious risk of bias using ROBINS-I
- b. The population included in the studies are healthy participants without an increased risk of IMD
- c. Low sample size (<400 participants). Confidence intervals overlap within some strains
- d. Very low sample size (<50 participants)
- e. Low number of events (<300 events)

Evidence to Decision Framework: Individual perspective

Should people at increased risk of IMD previously vaccinated with a meningococcal B vaccine primary series receive a booster Meningococcal B vaccination?					
Population	Infants, children, adolescents/young adults at increased medical/occupational risk of invasive meningococcal B				
Intervention	Booster dose of Bexsero (recombinant multicomponent meningococcal group B vaccine)				
Comparison	No booster				
Main outcomes	Efficacy/Effectiveness of booster dose Immunogenicity: hSBA \geq 1:4 / 1:5 (Bexsero) for test strains pre/post booster Immunogenicity: Geometric mean ratio of post/pre hSBA titres Local Solicited Adverse Events General/systemic solicited AEs Fever Unsolicited adverse events Serious Adverse Events				
Setting	US, Canada, Europe, Australia, United Kingdom, Chile				
Perspective	Individual				
ASSESSMENT					
Problem					
<i>Is the problem a priority?</i>					
Don't know	Varies	No	Probably No	Probably Yes	Yes
<ul style="list-style-type: none"> Invasive meningococcal disease (IMD) is a life-threatening infection with high rates of morbidity and mortality. Even with antibiotic treatment, the mortality rate for B strain in Australia is approximately 4%.¹⁰⁻¹² Survivors of infection are often left with permanent sequelae including limb / digit amputations, deafness and neurological deficits.¹¹ Risk of meningococcal disease is substantially increased in certain medical conditions including asplenia, complement deficiency and treatment with eculizumab. This can be up to 10,000 times higher than the general population in people with genetic deficiencies of the complement pathway.¹³ 					
Desirable effects					
<i>How substantial are the desirable anticipated effects?</i>					
Don't know	Varies	Large	Moderate	Small	Trivial

- All evidence is derived from booster studies in healthy individuals.
- There is evidence of a moderate effect from a booster dose of Bexsero, based on immunogenicity data only, which increases the proportion with hSBA \geq 1:4 or 1:5 (the proposed correlate of protection) but the increase varies in size dependent on test strain and on the degree of waning prior to the booster dose.
- Evidence of persistence is of very low certainty and immunogenicity data is limited to \leq 2 years following the booster. The rate of waning appears to vary by strain after booster and may be similar to or slower than after primary vaccination.
- There is no evidence available on clinical outcomes after booster doses.

Undesirable Effects

How substantial are the undesirable anticipated effects?

Don't know	Varies	Large	Moderate	Small	Trivial
------------	--------	-------	----------	-------	---------

- Undesirable effects include frequent rates of local adverse events and systemic adverse events which are mostly of mild to moderate severity. Rates are similar to those seen after primary vaccination in vaccine-naïve cohorts within the booster studies.
- There were no vaccine related serious adverse events due to the vaccine in the included booster studies.

Certainty of evidence

What is the overall certainty of the evidence of effects?

No Included Studies	Very Low	Low	Moderate	High
---------------------	----------	-----	----------	------

- The certainty of evidence is very low due to absence of studies of boosters specifically in populations at increased medical risk of IMD, small study sizes, non-randomised observational studies, and evaluation of single arm data.
- The certainty of evidence for risks and benefits for individuals who are healthy but at increased occupational / exposure risk would be low, similar to that for Bexsero in healthy individuals at standard background risk of IMD (PICO 1a).
- There is additional uncertainty in how immunogenicity findings correlate to clinical benefit against serogroup B meningococcal disease. However, inferring efficacy from immunogenicity has generally been accepted due to the rarity of the disease.

Values

Is there important uncertainty about or variability in how much people value the main outcomes?

Important uncertainty	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability
-----------------------	---	--	---

- Unlikely to be important uncertainty in how people value protection against invasive meningococcal disease.
- Individuals at increased risk of IMD are likely to still consider protection based on immunogenicity evidence as worthwhile.

Balance of effects

Does the balance between desirable and undesirable effects favour the intervention or the comparison?

Don't Know	Varies	Favours comparison	Probably favours comparison	Does not favour either comparison or intervention	Probably favours intervention	Favours intervention
------------	--------	--------------------	-----------------------------	---	-------------------------------	----------------------

- The overall improvement and likely prolongation of protection from a booster dose is likely to outweigh the additional frequency of non-serious adverse events/reactogenicity compared to no booster, particularly where the baseline risk of IMD is high.
- Undesirable effects are minor

Acceptability

Is the intervention acceptable to key stakeholders?

Don't know	Varies	No	Probably No	Probably Yes	Yes
------------	--------	----	-------------	--------------	-----

- Vaccination to prevent meningococcal disease appears to be acceptable in the Australian setting. There is high uptake of the MenACWY NIP-funded vaccine with 93.6% coverage by 2 years of age.¹⁴ Meningococcal B vaccine which is not funded has low coverage nationally (only 1.65% of adolescents in 2019)¹⁵, but is likely to be higher in South Australia where it is freely available under state funding. In a large state-wide South Australian study of the impact of vaccination with Bexsero on nasopharyngeal carriage of N. meningitidis in adolescents ('B Part of It'), 99.5% of those enrolled received 1 dose and 97% received 2 doses.

Feasibility

Is the intervention feasible to implement?

Don't know	Varies	No	Probably No	Probably Yes	Yes
------------	--------	----	-------------	--------------	-----

- Vaccine delivery system already exists. Small numbers as the population at increased risk of IMD is low and uptake nationally is low.

References

1. Vesikari T, Østergaard L, Beeslaar J, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents. *Vaccine* 2019;37:1710-9.
2. Snape MD, Voysey M, Finn A, et al. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. *Pediatr Infect Dis J* 2016;35:e113-23.
3. Sadarangani M, Sell T, Iro MA, et al. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. *CMAJ* 2017;189:E1276-E85.
4. Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. *CMAJ* 2013;185:E715-24.
5. Snape MD, Philip J, John TM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. *Pediatr Infect Dis J* 2013;32:1116-21.
6. Nolan T, Santolaya ME, de Looze F, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. *Vaccine* 2019;37:1209-18.
7. Martinon-Torres F, Carmona Martinez A, Simko R, et al. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial. *J Infect* 2018;76:258-69.
8. Szenborn L, Block SL, Jackowska T, et al. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study. *Pediatr Infect Dis J* 2018;37:475-82.
9. Iro MA, Snape MD, Voysey M, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age—a phase 3 extension to a randomised controlled trial. *Vaccine* 2017;35:395-402.
10. Archer BN, Chiu CK, Jayasinghe SH, et al. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination. *Med J Aust* 2017;207:382-7.
11. Deng LC, Barton B, Lorenzo J, et al. Longer term outcomes following serogroup B invasive meningococcal disease. *JOURNAL OF PAEDIATRICS AND CHILD HEALTH*.
12. Martin NV, Ong KS, Howden BP, et al. Rise in invasive serogroup W meningococcal disease in Australia 2013-2015. *Commun Dis Intell* 2016;40:E454-9.
13. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. *Clin Microbiol Rev* 1991;4:359-95.
14. National Centre for Immunisation Research and Surveillance. Annual Immunisation Coverage Report 2019. Available from: <https://ncirs.org.au/sites/default/files/2020-11/NCIRS%20Annual%20Immunisation%20Coverage%20Report%202019%20Final.pdf> (Accessed 4/11/2021).
15. de Oliveira Costa J, Gianacas C, Beard F, et al. Cumulative annual coverage of meningococcal B vaccination in Australian general practice for three at-risk groups, 2014 to 2019. *Hum Vaccin Immunother* 2021;17:3692-701.
16. Lahra MM, Enriquez R. Australian Meningococcal Surveillance Programme annual report, 2016. *Commun Dis Intell Q Rep* 2017;41:E369-E82.
17. Lahra MM, Enriquez RP, George CRR. Australian Meningococcal Surveillance Programme annual report, 2017. *Commun Dis Intell (2018)* 2019;43.
18. Lahra MM, Enriquez RP, Hogan TP, National Neisseria N. Australian Meningococcal Surveillance Programme annual report, 2018. *Commun Dis Intell (2018)* 2020;44.
19. Lahra MM, George CRR, Shoushtari M, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2020. *Commun Dis Intell (2018)* 2021;45.
20. Lahra MM, Hogan TR, National Neisseria Network A. Australian Meningococcal Surveillance Programme annual report, 2019. *Commun Dis Intell (2018)* 2020;44.
21. Martinon-Torres F, Bernatowska E, Shcherbina A, et al. Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. *Pediatrics* 2018;142.
22. van den Broek B, van Els C, Kuipers B, et al. Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency. *Clinical and Experimental Immunology* 2019;198:381-9.

23. Read RC, Dull P, Bai X, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. *Vaccine* 2017;35:427-34.
24. Vesikari T, Prymula R, Merrall E, et al. Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. *Vaccine* 2015;33:3850-8.
25. Deceuninck G, Lefebvre B, Tsang R, et al. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. *Vaccine* 2019;37:4243-5.
26. Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. *N Engl J Med* 2020;382:309-17.
27. Martinon-Torres F, Banzhoff A, Azzari C, et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. *J Infect* 2021;83:17-26.
28. Tozer SJ, Smith HV, Whitley DM, et al. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007–2011: Concordant predictions between MATS and genetic MATS. *Hum Vaccin Immunother* 2021;17:3230-8.
29. Findlow J, Lucidarme J, Taha M-K, Burman C, Balmer P. Correlates of protection for meningococcal surface protein vaccines: lessons from the past. *Expert Rev Vaccines* 2021:1-13.
30. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against *Neisseria meningitidis* serogroup B disease. *Vaccine* 2003;21:734-7.